Determining whether to patent an AI-implemented invention, especially one embodying a life science related innovation or technology, is a difficult assessment. And drafting a related patent application is also extremely difficult given the complexity of the law, the abhorrence of abstractness and the very nature that AI on some level must be abstract to be useful.
In this webinar, we will review current approaches for deciding whether to patent an AI-implemented biotechnology, pharmaceutical, or medical device invention, or whether the best course of action is to keep the innovation as a trade secret.
Join Gene Quinn, President & CEO of IPWatchdog, Inc., as he moderates a wide-ranging discussion on the intersection of artificial intelligence and life sciences. Joining Gene will be Bruce Wu, Director of Global IP for Illumina, Kevin Buckley, Founder of Torrey Pines Law Group, Neil Thompson, Patent Agent at Torrey Pines Law Group, and Steve Walsh, Senior Manager for Business Development at Morningside IP.
In addition to taking as many questions as possible, we will also discuss: